■ Nova Eye Medical has been granted 510(k) clearance from the US Food and Drug Administration to market its iTrack Advance canaloplasty device in the United States. The device has been cleared for microcatheterization and viscodilation, to reduce IOP in adult patients with primary open-angle glaucoma. This device leverages the same proprietary features of the company’s original iTrack, including a 200-μm illuminated canaloplasty microcatheter, but also features an ergonomic handpiece that facilitates improved access into the canal.

“Thanks to the handpiece, we can advance the microcatheter and then retract it along the full circumference of Schlemm’s canal with much greater efficiency than ever before,” Mahmoud A. Khaimi, MD, said in a news release. Dr. Khaimi was the first surgeon in the United States to perform canaloplasty with the iTrack Advance.